BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Perumpail RB, Liu A, Wong RJ, Ahmed A, Harrison SA. Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways. World J Hepatol 2015; 7(22): 2384-2388 [PMID: 26464753 DOI: 10.4254/wjh.v7.i22.2384]
URL: https://www.wjgnet.com/1948-5182/full/v7/i22/2384.htm
Number Citing Articles
1
V. P. Prysyazhnyuk, Z. I. Rossokha, N. G. Gorovenko. Variation in particular biochemical indicators, cytokine and adipokine profiles of the blood, and the structural and functional parameters of the liver in patients with nonalcoholic fatty liver disease and different genotypes by the polymorphic locus A313G of the GSTP1 geneCytology and Genetics 2017; 51(6): 455 doi: 10.3103/S0095452717060111
2
Abhilash Perisetti, Hemant Goyal, Rachana Yendala, Ragesh B Thandassery, Emmanouil Giorgakis. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancementsWorld Journal of Gastroenterology 2021; 27(24): 3466-3482 doi: 10.3748/wjg.v27.i24.3466
3
Yu-Wen Su, Po-Hong Liu, Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Shu-Yein Ho, Ming-Chih Hou, Harn-Shen Chen, Teh-Ia Huo, Sheng-Nan Lu. Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspectivePLOS ONE 2017; 12(3): e0174333 doi: 10.1371/journal.pone.0174333
4
Pegah Golabi, James Paik, Natsu Fukui, Cameron T. Locklear, Leyla de Avilla, Zobair M. Younossi. Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for MortalityClinical Diabetes 2019; 37(1): 65 doi: 10.2337/cd18-0026
5
Ozlem Kucukoglu, Jan-Peter Sowa, Guillermo Daniel Mazzolini, Wing-Kin Syn, Ali Canbay. Hepatokines and adipokines in NASH-related hepatocellular carcinomaJournal of Hepatology 2021; 74(2): 442 doi: 10.1016/j.jhep.2020.10.030
6
Meenakshi Vachher, Savita Bansal, Bhupender Kumar, Sandeep Yadav, Archana Burman. Deciphering the role of aberrant DNA methylation in NAFLD and NASHHeliyon 2022; 8(10): e11119 doi: 10.1016/j.heliyon.2022.e11119
7
Luca Rinaldi, Fabio Nascimbeni, Mauro Giordano, Chiara Masetti, Barbara Guerrera, Annalisa Amelia, Maria Chiara Fascione, Stefano Ballestri, Dante Romagnoli, Rosa Zampino, Riccardo Nevola, Enrica Baldelli, Natalina Iuliano, Valerio Rosato, Amedeo Lonardo, Luigi Elio Adinolfi. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosisWorld Journal of Gastroenterology 2017; 23(8): 1458-1468 doi: 10.3748/wjg.v23.i8.1458
8
Georgi Atanasov, Karoline Dino, Katrin Schierle, Corinna Dietel, Gabriela Aust, Johann Pratschke, Daniel Seehofer, Moritz Schmelzle, Hans-Michael Hau. Angiogenic inflammation and formation of necrosis in the tumor microenvironment influence patient survival after radical surgery for de novo hepatocellular carcinoma in non-cirrhosisWorld Journal of Surgical Oncology 2019; 17(1) doi: 10.1186/s12957-019-1756-8
9
Ryota Masuzaki, Seth J. Karp, Masao Omata. NAFLD as a risk factor for HCC: new rules of engagement?Hepatology International 2016; 10(4): 533 doi: 10.1007/s12072-016-9731-8
10
Fahimeh Tabakhiyan, Amirabbas Mir, Vahid Vahedian. Potential tumor marker for hepatocellular carcinoma identification: PI3K and pro-inflammatory cytokines (TGF-β, IL-1, and IL-6)Hormone Molecular Biology and Clinical Investigation 2022; 43(4): 389 doi: 10.1515/hmbci-2022-0028
11
Shenghu Feng, Ming Han, Li Zhou, Qi Wang, Zhongshu Li, Yaru Li, Hongping Lu, Ting Liu, Yanhua Ma, Shunai Liu, Jun Cheng. NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesisCancer Science 2017; 108(1): 12 doi: 10.1111/cas.13117
12
Chee-Kiat Tan. Peretinoin as an adjuvant therapy for hepatocellular carcinomaExpert Review of Gastroenterology & Hepatology 2016; 10(11): 1201 doi: 10.1080/17474124.2016.1238303
13
Max Kabolowsky, Lyndsey Nguyen, Brett E. Fortune, Ernesto Santos, Sirish Kishore, Juan C. Camacho. Interventional Management of Portal Hypertension in Cancer PatientsCurrent Oncology Reports 2022; 24(11): 1461 doi: 10.1007/s11912-022-01319-8
14
Kanokwan Pinyopornpanish, Wael Al-Yaman, Srinivasan Dasarathy, Carlos Romero-Marrero, Arthur McCullough. Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and SurvivalDigestive Diseases and Sciences 2022; 67(6): 2677 doi: 10.1007/s10620-021-07048-5
15
Rupie Jamwal, Venkatram Krishnan, Dinesh Singh Kushwaha, Rajat Khurana. Hepatocellular carcinoma in non-cirrhotic versus cirrhotic liver: a clinico-radiological comparative analysisAbdominal Radiology 2020; 45(8): 2378 doi: 10.1007/s00261-020-02561-z
16
Nikolaos-Andreas T. Anastasopoulos, Georgios D. Lianos, Vera Tatsi, Anastasia Karampa, Anna Goussia, Georgios K. Glantzounis. Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinomaExpert Review of Gastroenterology & Hepatology 2020; 14(11): 1025 doi: 10.1080/17474124.2020.1802244
17
Qiong Wu, Jin-xian Chen, Yu Chen, Li-li Cai, Xiao-zhong Wang, Wu-hua Guo, Jian-feng Zheng. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activationCell Death & Disease 2018; 9(2) doi: 10.1038/s41419-018-0267-9
18
Elizabeth R. M. Zunica, Elizabeth C. Heintz, Christopher L. Axelrod, John P. Kirwan. Obesity Management in the Primary Prevention of Hepatocellular CarcinomaCancers 2022; 14(16): 4051 doi: 10.3390/cancers14164051
19
Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver CancerCancers 2019; 11(11): 1626 doi: 10.3390/cancers11111626
20
А.М. Абд Эль-Хамид, А.И. Юсеф, С.М. Абд Эль-Тваб, А.А.Г. Эль-Шахави, А. Абдель-Монеим. Гепатопротекторное действие нагруженных полидатином хитозановых наночастиц у крыс с сахарным диабетом: модуляция метаболизма глюкозы, окислительного стресса и биомаркеров воспалительных процессовБиохимия 2021; 86(2): 214 doi: 10.31857/S0320972521020068
21
Zobair M. Younossi, Linda Henry. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinomaJHEP Reports 2021; 3(4): 100305 doi: 10.1016/j.jhepr.2021.100305
22
Tushar Prabhakar, Kanica Kaushal, Manya Prasad, Ekta Gupta, Ajit Sood, Ajay K. Jain, Akash Shukla, Ashish Goel, Ajay Duseja, Anoop Saraya, Samir Shah, Guresh Kumar, Shiv Kumar Sarin. Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric studyHepatology International 2023; 17(3): 745 doi: 10.1007/s12072-023-10498-w
23
Aakash Desai, Sonia Sandhu, Jin-Ping Lai, Dalbir Singh Sandhu. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive reviewWorld Journal of Hepatology 2019; 11(1): 1-18 doi: 10.4254/wjh.v11.i1.1
24
Caitlin A. McIntyre, Joanne F. Chou, Mithat Gonen, Jinru Shia, Maya Gambarin-Gelwan, Vinod P. Balachandran, T. Peter Kingham, Peter J. Allen, Jeffrey A. Drebin, William R. Jarnagin, Michael I. D'Angelica. Hepatocellular carcinoma in patients with no identifiable risk factorsHPB 2021; 23(1): 118 doi: 10.1016/j.hpb.2020.05.005
25
Vasyl Prysyazhnyuk, Larysa Sydorchuk, Ruslan Sydorchuk, Iryna Prysiazhniuk, Kateryna Bobkovych, Inna Buzdugan, Valentina Dzuryak, Petro Prysyazhnyuk. Glutathione-S-transferases genes-promising predictors of hepatic dysfunctionWorld Journal of Hepatology 2021; 13(6): 620-633 doi: 10.4254/wjh.v13.i6.620
26
Annalisa Cespiati, Felice Cinque, Marica Meroni, Rosa Lombardi, Paola Dongiovanni, Anna Ludovica Fracanzani. An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for PhysiciansBiomedicines 2023; 11(2): 586 doi: 10.3390/biomedicines11020586
27
Y. E. Chon, K. S. Jung, M.‐J. Kim, J.‐Y. Choi, C. An, J. Y. Park, S. H. Ahn, B. K. Kim, S. U. Kim, H. Park, S. K. Hwang, K. S. Rim, K.‐H. Han, D. Y. Kim. Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillanceAlimentary Pharmacology & Therapeutics 2018; 47(8): 1201 doi: 10.1111/apt.14578
28
Zurabi Lominadze, Mohammed Rifat Shaik, Dabin Choi, Duha Zaffar, Lopa Mishra, Kirti Shetty. Hepatocellular Carcinoma Genetic ClassificationThe Cancer Journal 2023; 29(5): 249 doi: 10.1097/PPO.0000000000000682
29
Zobair M. Younossi, Linda Henry, Scott Isaacs, Kenneth Cusi. Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology ClinicsEndocrine Practice 2023; 29(11): 912 doi: 10.1016/j.eprac.2023.06.012
30
V. Prysyazhnyuk. Clinical-pathagenetic, Age, Gender, Genetic Aspects of Non-alcoholic Fatty Liver Disease and Nonviral Chronic Hepatitis Without, and also with Comorbid Hypothyroidism; Improving of Their TreatmentLviv clinical bulletin 2018; 3(23): 8 doi: 10.25040/lkv2018.03.008
31
K. Reyes-Gordillo, R. Shah, M.R. Lakshman, R.E. Flores-Beltrán, P. Muriel. Liver Pathophysiology2017; : 687 doi: 10.1016/B978-0-12-804274-8.00049-7
32
Yilin Tian, Jing Lu, Yongxia Qiao. A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinomaFrontiers in Molecular Biosciences 2022; 9 doi: 10.3389/fmolb.2022.988323
33
Lai Xue, Kun Wu, Hongmei Qiu, Bo Huang, Rongchun Chen, Wei Xie, Qingsong Jiang. Polydatin exhibits the hepatoprotective effects through PPAR-α/-β signaling pathway in Streptozocin-induced diabetic miceJournal of Functional Foods 2017; 36: 341 doi: 10.1016/j.jff.2017.07.015